<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348787</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/17/0159</org_study_id>
    <secondary_id>2017-A01929-44</secondary_id>
    <nct_id>NCT03348787</nct_id>
  </id_info>
  <brief_title>Behavioral and Cognitive Therapies for Auditory Hallucination Management</brief_title>
  <acronym>AcceptVoice</acronym>
  <official_title>Behavioral and Cognitive Therapies for Auditory Hallucination Management: Effectiveness and Analysis of Change Processes Involved With Hallucinations in a Population Suffering From Chronic Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study wants to evaluate the efficacy of a short psychoeducational type group&#xD;
      intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory&#xD;
      Acoustico-Verbal (HAV) symptomatology in patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intensity HAV symptoms</measure>
    <time_frame>Baseline and one week after the last session</time_frame>
    <description>Difference between the Psychotic Symptom Rating Scales (PSYRATS) on HAV symptom score administered before the first therapeutic group session and the PSYRATS symptom score administered 1 week after the last group session. The PSYRATS Scales measure dimensions of hallucinations and delusions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect over time</measure>
    <time_frame>Until 12 months after the last session</time_frame>
    <description>Difference between the PSYRATS score given 1 week before the first session, and the PSYRATS score administered one week after the last session and then at 6 weeks, 6 months and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Chronic Psychosis</condition>
  <arm_group>
    <arm_group_label>Behavioral and Cognitive Therapies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic psychotic patients will have Behavioral and Cognitive Therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral and Cognitive Therapies</intervention_name>
    <description>Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave &quot;Accept Voices&quot; applied to HAV</description>
    <arm_group_label>Behavioral and Cognitive Therapies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Schizophrenic disorders, schizo-affective disorders&#xD;
&#xD;
          -  Suffering from persistent HAV&#xD;
&#xD;
          -  No change in symptomatology for 3 months.&#xD;
&#xD;
          -  No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine,&#xD;
             risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol,&#xD;
             modecate, nozinan, cyamemazine, piportil, clozapine&#xD;
&#xD;
          -  Major patient, or major incompetent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Subject participating in another search including an exclusion period still in&#xD;
             progress at pre-inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Bourcier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lannemezan Hospital</name>
      <address>
        <city>Lannemezan</city>
        <zip>65300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lavaur Hospital</name>
      <address>
        <city>Lavaur</city>
        <zip>81502</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte-Marie de Rodez Hospital</name>
      <address>
        <city>Rodez</city>
        <zip>12032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ariège-Couserans Hospital</name>
      <address>
        <city>Saint-Lizier</city>
        <zip>09190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gérard Marchand Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31057</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Behavioral and Cognitive Therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

